文献速递MDS 与骨髓增殖性肿瘤

来那度胺在非输血依赖型骨髓增生异常综合征患者中的使用影响

Impact of lenalidomide use among non-transfusion dependent patients with myelodysplastic syndromes.
PubMed 文献 · Am J Hematol · 2018-08-28

该研究基于SEER-Medicare数据库,分析2007至2013年确诊的65岁及以上MDS患者中来那度胺的使用与结局。676例使用者中40.7%为输血依赖(TD)、59.3%为非TD;非TD患者血栓栓塞事件发生率高于TD患者(10.8% vs. 6.0%,P = .04);与风险匹配对照相比,确诊6个月内使用来那度胺的非TD患者总生存无改善(P = .78)。

要点

  • 非TD患者占来那度胺使用者的59.3%(401/676),其中18.5%(125/676)用药前无红细胞输注记录。
  • 非TD患者血栓栓塞事件发生率高于TD患者(10.8% vs. 6.0%,P = .04)。
  • TD患者中31%达输血独立、30%达轻微血液学反应,中位至输血独立时间4.1周。

核心结论

  • 研究证实来那度胺对输血依赖型MDS患者有益,但许多非输血依赖患者也使用了来那度胺,这些患者承受伴随毒性而无输血需求或总生存方面的获益证据。

研究设计与样本

  • 利用SEER数据库识别2007至2013年确诊的65岁及以上MDS患者,并链接Medicare理赔数据评估输血、来那度胺使用及新发毒性。
  • 输血依赖定义为8周内至少2次输血事件;疗效反应包括输血独立和输血减少≥50%(轻微反应)。
  • 将接受来那度胺的非TD患者与按疾病和患者特征匹配的未接受来那度胺患者比较总生存。
  • 共识别676例接受来那度胺的患者,其中275例(40.7%)为TD、401例(59.3%)为非TD;18.5%(125/676)在用药前无红细胞输注理赔记录。
  • 将191例确诊MDS后6个月内使用来那度胺的非TD患者与风险匹配的MDS对照比较总生存。

主要发现

  • 接受来那度胺的患者中新发毒性在TD与非TD组相似,唯独非TD组血栓栓塞事件发生率更高(10.8% vs. 6.0%,P = .04)。
  • 在191例确诊6个月内使用来那度胺的非TD患者中,与风险匹配对照相比,来那度胺与总生存改善无关(P = .78)。
  • 在275例TD患者中,31%达输血独立,30%达轻微血液学反应,中位至输血独立时间为4.1周。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Chemotherapies approved for defined subgroups promise personalized oncologic care, but their off-label impact is unclear. Lenalidomide is approved for lower-risk, transfusion-dependent (TD) myelodysplastic syndromes (MDS) with del(5q), but frequently used in MDS outside this indication. We characterized lenalidomide use and outcomes among non-TD patients with MDS. Patients 65 or older diagnosed with MDS between 2007 and 2013 were identified using SEER; linked Medicare claims were evaluated for transfusions, lenalidomide use, and incident toxicities. TD was ≥2 transfusion episodes within an 8-week period; responses were transfusion independence (TI) and ≥50% transfusion reduction (minor response). We compared overall survival for non-TD patients receiving lenalidomide versus those not receiving lenalidomide, matched on disease and patient characteristics. We identified 676 patients who had received lenalidomide, including 275 (40.7%) TD and 401 (59.3%) non-TD; 18.5% (125/676) had zero claims for RBC transfusion prior to receiving lenalidomide. Incident toxicities among patients prescribed lenalidomide were similar in TD and non-TD groups, except incident thromboembolic events were higher among non-TD patients (10.8% vs. 6.0%, P = .04). Comparing 191 non-TD patients receiving lenalidomide within 6 months of MDS diagnosis to risk-matched MDS controls, lenalidomide was not associated with improved OS (P = .78). Among TD patients (n = 275), 31% achieved TI, and 30% achieved minor hematologic response, with a median time to TI of 4.1 weeks. In conclusion, we confirmed the benefit of lenalidomide among TD patients with MDS; however, many non-TD patients also received lenalidomide. These patients experienced accompanying toxicity without evidence of benefit in terms of transfusion needs or overall survival.

来源:Am J Hematol,查看原文。版权归原作者所有。

引用

  1. Brunner AM, Weng S, Cronin A, et al. Impact of lenalidomide use among non-transfusion dependent patients with myelodysplastic syndromes. Am J Hematol. 2018. PMID: 30033577. doi:10.1002/ajh.25166

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。